DPP-4 inhibitors

DPP-4 inhibitors has been studied in 518 papers since 2012: 5 trials and 328 observational studies in people, 7 in animals, 1 in cells, 168 reviews; 292 in the past year. The newest story, Nov 12, 2026: “Diabetes drug class not linked to higher kidney injury risk”.

Intervention

518 papers study it169 findingsUpdated

78 new papers in 30 daysSee all 514 papers on DPP-4 inhibitors

At a glance

DPP-4 inhibitors are linked with lower Parkinson’s disease risk in people with diabetes, with independent labs reporting the link again, although other studies find no clear link. Independent labs report reduced inflammation in mice, and one mouse atherosclerosis study reports reduced senescent cell burden. Some authors work at companies, and some papers declare company ties.

169 findings in 111 papers from 2012 to 2026, 25 of them since April 2026

Independent labs found the same change in mice and people. 75 independent labs in 22 countries.

“DPP4i were associated with a lower risk of certain psychiatric disorders, Parkinson's disease (0.54 [0.32, 0.92])”
Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trialsDiabetes, obesity & metabolism2024doi:10.1111/dom.16147

12 of its findings point the other way.

Mice and humans: replicated by independent labs. Cells: a single group. Worms or flies: nothing yet.
  • 75 independent labs in 22 countries
  • 12 findings against
  • Funders: National Institute on Aging and others
  • 27 of 138 findings with company ties
  • Human trial5
  • Humans327
  • Animals7
  • Cells1
  • In silico6

Studies in people

4 studies gave DPP-4 inhibitors to people and measured what changed.

What changedDesignPeopleSource

down: Decreases phosphorylated tau 181β = -0.39, P < 0.05

down: Decreases amyloid-beta composite biomarker-0.5 ± 0.7 vs. 0.0 ± 0.7, P = 0.02

no change: Has no effect on NfL

Treated cohort18 months43 peopleBotholder adultsOlder adults; in older adults with type 2 diabetesAAIC 2025 abstract, Dec 25, 2025

down: Lowers the risk of Parkinson's diseaseOR 0.54 (95% CI 0.32–0.92)

Review of trials198,177 people pooledPatient cohortsDiabetes, obesity & metabolism, Dec 26, 2024

down: Decreases blood glucose

up: Improves cognitive ability

up: Increases Aβ1-42/Aβ1-40 ratio

Trialsix months30 peopleelderlyOlder adults; within-group change in patients with type 2 diabetes and post-stroke MCI; no difference from sulfonylureaExperimental and therapeutic medicine, Dec 17, 2019

up: Raises the risk of headacheOR 1.22 (95% CI 1.02 to 1.46) vs insulin

down: Lowers the risk of dizzinessOR 0.76 (95% CI 0.67 to 0.87)

Review of trials147,710 people pooledPatient cohortsAging and disease, Dec 1, 2019

What did studies of DPP-4 inhibitors find?

74

Studies of DPP-4 inhibitors measured 74 outcomes; the most studied are inflammation (6 studies), HbA1c (4) and cellular senescence (3).

Inflammation

downin reviews2downin human cells1downin humans1downin mice1+1

6 studies
  1. DPP-4 inhibitors are linked with lower inflammation in T2DM patients with acute ischemic stroke (P<0.05).

    “inflammatory and oxidative stress marker levels were decreased”

    Humansin T2DM patients with acute ischemic stroke6 monthsn = 236

    DPP-4 inhibitors for preventing post-stroke cognitive impairment in diabetic patients with acute ischemic stroke: a retrospective cohort study

    American journal of translational research

  2. DPP-4 inhibitors decrease inflammation.

    “A similar effect was observed with dipeptidyl peptidase-4 inhibitors.”

    Review

    New opportunities for the use of hypoglycemic drugs in the treatment of osteoarthritis

    Медицина: теория и практика

  3. DPP-4 inhibitors decrease inflammation (diabetes-associated neurovascular impairment).

    “DPP-4 inhibitors exert dual neuroprotective actions by enhancing incretin signaling (GLP-1/GIP), which supports synaptic plasticity and attenuates neuroinflammation”

    Reviewdiabetes-associated neurovascular impairmentbrain

    Neurovascular Actions of Dipeptidyl Peptidase-4 Inhibitors and Their Implications for Cognitive Dysfunction in Type 2 Diabetes Mellitus

    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

  4. DPP-4 inhibitors decrease inflammation in 6-OHDA lesioned rats.

    “Post-treatment with a threefold higher oral gliptin dose, likewise, mitigated meth-induced rotation, dopaminergic neurodegeneration and neuroinflammation, and augmented neurogenesis.”

    Animalsin 6-OHDA lesioned ratsbrain

    DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease

    GeroScience

  5. DPP-4 inhibitors decrease inflammation in human cells (hydrogen peroxide-treated endothelial cells).

    “In vitro, the inhibition of DPP-4 also alleviated the changes in the oxidative and inflammatory molecules in response to hydrogen peroxide in human umbilical vein endothelial cells.”

    Cellshydrogen peroxide-treated endothelial cells

    Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: Modulation of oxidative stress and inflammation

    Chemico-biological interactions

  6. DPP-4 inhibitors decrease inflammation in db/db mice fed either diet.

    “DPP-4 inhibition improves glucose tolerance, β cell function, and adipose tissue inflammation in db/db mice fed either diet.”

    Animalsin db/db mice fed either dietadipose tissue

    DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid

    Diabetology & metabolic syndrome

More on Inflammation

HbA1c

downin humans3downin reviews1

4 studies
  1. DPP-4 inhibitors are linked with lower HbA1c in humans (between-group comparison in a switch design) (β -0.26 (95% CI -0.51 to -0.01)).

    “Switching to DPP-4 inhibitors was associated with a greater reduction in HbA1c (β, -0.26; 95% confidence interval [CI], -0.51 to -0.01; P<0.001).”

    Humansbetween-group comparison in a switch design3 monthsn = 168

    Comparative Clinical Analysis of DPP-4 inhibitors and SGLT2 Inhibitors: A Real-World Switch Study

    Journal of obesity & metabolic syndrome

  2. DPP-4 inhibitors decrease HbA1c (approximately 0.6-1.1%).

    “DPP-4is provide clinically meaningful HbA1c reductions, approximately 0.6-1.1%, with a low risk of hypoglycemia”

    Review

    DPP-4 inhibitors in current diabetes care: their foundational role in treating to target

    Diabetes research and clinical practice

  3. DPP-4 inhibitors decrease HbA1c in humans (type 2 diabetes and stage 4-5 CKD) (-0.54% to -0.72%).

    “DPP-4 inhibitors reduced HbA1c by - 0.54% to - 0.72%, with low rates of severe hypoglycemia (4-5%).”

    Reviewtype 2 diabetes and stage 4-5 CKDn = 1,800

    Comparative efficacy and safety of non-insulin antihyperglycemic agents versus insulin in patients over 65 years with type 2 diabetes and advanced or end-stage chronic kidney disease on dialysis: a systematic review of studies published in the last 10 years

    Journal of diabetes and metabolic disorders

  4. DPP-4 inhibitors decrease HbA1c in humans (at HbA1c <8.0% to 8.5%, as add-on to metformin, compared with SGLT2i) (slightly greater than SGLT2i).

    “At HbA1C <8.0% to 8.5%, HbA1C lowering is slightly greater with DPP-4i than with SGLT2i as an add-on to metformin”

    Reviewat HbA1c <8.0% to 8.5%, as add-on to metformin, compared with SGLT2i

    Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial

    Clinical therapeutics

More on HbA1c

Cellular senescence

downin reviews2downin human cells1

3 studies
  1. DPP-4 inhibitors decrease cellular senescence in HDFs.

    “Inhibition of DPP4 mitigated ferroptosis-associated senescence”

    Cellsin HDFsskin

    HIF-1α attenuates ferroptosis-associated dermal fibroblast senescence via modulation of NF-κB-DPP4 signaling

    Journal of translational medicine

  2. DPP-4 inhibitors decrease cellular senescence (stress induced accelerated senescence).

    “strong beneficial effects on the stress induced accelerated senescence of vascular cells”

    Reviewstress induced accelerated senescencevascular cells

    Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control

    Clinical medicine insights. Endocrinology and diabetes

  3. DPP-4 inhibitors inhibit cellular senescence in humans and animal models of type 2 diabetes mellitus.

    “alleviating EC senescence”

    Reviewin humans and animal models of type 2 diabetes mellitus

    Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging

    Frontiers in endocrinology

More on Cellular senescence

Oxidative stress and ROS signaling

downin human cells1downin humans1downin reviews1

3 studies
  1. DPP-4 inhibitors are linked with lower oxidative stress and ROS signaling in T2DM patients with acute ischemic stroke (P<0.05).

    “inflammatory and oxidative stress marker levels were decreased”

    Humansin T2DM patients with acute ischemic stroke6 monthsn = 236

    DPP-4 inhibitors for preventing post-stroke cognitive impairment in diabetic patients with acute ischemic stroke: a retrospective cohort study

    American journal of translational research

  2. DPP-4 inhibitors decrease oxidative stress and ROS signaling.

    “Additional benefits include modulation of the Nrf2/GPX4 axis, reducing oxidative stress and ferroptosis in neural tissue.”

    Reviewneural tissue

    Neurovascular Actions of Dipeptidyl Peptidase-4 Inhibitors and Their Implications for Cognitive Dysfunction in Type 2 Diabetes Mellitus

    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

  3. DPP-4 inhibitors decrease oxidative stress and ROS signaling in human cells (hydrogen peroxide-treated endothelial cells).

    “In vitro, the inhibition of DPP-4 also alleviated the changes in the oxidative and inflammatory molecules in response to hydrogen peroxide in human umbilical vein endothelial cells.”

    Cellshydrogen peroxide-treated endothelial cells

    Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: Modulation of oxidative stress and inflammation

    Chemico-biological interactions

More on Oxidative stress and ROS signaling

Mortality

downin humans1no changein humans1downin mice1HR 0.97

3 studies
  1. DPP-4 inhibitors are linked with lower mortality in residents of LTCFs with diabetes receiving metformin compared with long-acting insulin (sHR 0.82 (95% CI, 0.76-0.90)).

    “and all-cause mortality (sHR, 0.82; 95% CI, 0.76-0.90) was observed in DPP-4 initiators compared with long-acting insulin.”

    Humansin residents of LTCFs with diabetes receiving metformin compared with long-acting insulin5-year follow-upn = 4,414

    Cardiovascular Safety of Dipeptidyl Peptidase 4 Inhibitors Compared With Insulin or Sulfonylureas Added to Metformin Among Older People With Diabetes Living in Long-Term Care Facilities

    Journal of the American Medical Directors Association

  2. DPP-4 inhibitors were not clearly linked with mortality in humans (nursing home residents) (HR = 0.97, 95% CI 0.86-1.10).

    “and death (HR = 0.97, 95% CI 0.86-1.10).”

    Humansnursing home residents1 yearn = 2,016

    Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults

    Journal of the American Geriatrics Society

  3. DPP-4 inhibitors decrease mortality in SL-fed db/db mice.

    “DPP-4 inhibition reduces the early lethality in SL-fed db/db mice.”

    Animalsin SL-fed db/db mice

    DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid

    Diabetology & metabolic syndrome

Body weight

no changein humans2no changein reviews1

3 studies
  1. DPP-4 inhibitors showed no clear effect on body weight in humans.

    “Dipeptidyl peptidase-4 inhibitors are considered weight neutral medications.”

    Review

    Weight-centric treatment of type 2 diabetes mellitus

    Obesity pillars

  2. DPP-4 inhibitors showed no clear effect on body weight in humans.

    “they have a neutral effect on body weight”

    Review

    Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus

    Acta diabetologica

  3. DPP-4 inhibitors showed no clear effect on body weight.

    “Dipeptidyl peptidase-4 inhibitors are weight neutral and have few adverse effects.”

    Review

    When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy

    Diabetes/metabolism research and reviews

Stroke

no changein humans2RR 0.91

2 studies
  1. DPP-4 inhibitors were not clearly linked with stroke in type 2 diabetes.

    “SGLT2i and DPP-4i showed no clear associations with any stroke outcome.”

    Humansin type 2 diabetesn = 171,917

    The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis

    EClinicalMedicine

  2. DPP-4 inhibitors showed no clear effect on stroke in humans (diabetic individuals) (RR 0.91, 95% CI 0.83–1.01).

    “DPP4-Is use did not decrease the risk of non-fatal hemorrhagic or ischemic stroke (RR: 0.91; 95% CI [0.83, 1.01], p = 0.07)”

    Reviewdiabetic individuals

    The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials

    Frontiers in stroke

More on Stroke

Glucose tolerance

upin mice2

2 studies
  1. DPP-4 inhibitors improve glucose tolerance in mice (HFD-fed Gipr+/+ mice).

    “DPP-4 inhibition significantly improved glucose tolerance and attenuated body-weight gain in HFD-fed Gipr+/+ mice, without affecting food intake.”

    AnimalsHFD-fed Gipr+/+ micemales

    Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice

    Journal of diabetes investigation

  2. DPP-4 inhibitors improve glucose tolerance in db/db mice fed either diet.

    “DPP-4 inhibition improves glucose tolerance, β cell function, and adipose tissue inflammation in db/db mice fed either diet.”

    Animalsin db/db mice fed either diet

    DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid

    Diabetology & metabolic syndrome

Cognitive function

upin humans2

2 studies
  1. DPP-4 inhibitors are linked with better cognitive function in T2D patients on metformin combination therapy vs metformin alone.

    “T2D patients on combination therapy demonstrated better cognitive function, independent of other phenotypic, metabolic and biochemical factors.”

    Humansin T2D patients on metformin combination therapy vs metformin alone

    Repurposing SGLT2 and DPP-4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking

    British journal of pharmacology

  2. DPP-4 inhibitors improve cognitive function in humans (type 2 diabetes mellitus) (MMSE weighted mean difference 1.09, 95% CI 0.22 to 1.96).

    “Administration of DPP-4i generally correlated with an increase of Mini-Mental State Examination (MMSE) scores (1.09, 95% CI: 0.22 to 1.96).”

    Reviewtype 2 diabetes mellitusn = 5,178

    Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus

    Lipids in health and disease

Major adverse cardiovascular events

no changein humans2HR 0.9

2 studies
  1. DPP-4 inhibitors were not clearly linked with major adverse cardiovascular events in humans (versus sulfonylureas, used as a negative control comparison).

    “We did not observe large differences in MACE or HHF risks for DPP-4i vs. SU, in line with CAROLINA trial estimates.”

    Humansversus sulfonylureas, used as a negative control comparison

    Cardiovascular Effectiveness of SGLT2i and GLP-1RA vs. Sulfonylureas by Socioeconomic Status—Analysis of U.S. and UK Health Care Systems

    ADA Scientific Sessions 2025 abstract

  2. DPP-4 inhibitors were not clearly linked with major adverse cardiovascular events in humans (nursing home residents) (HR = 0.90, 95% CI 0.72-1.12).

    “AMI (HR = 0.76, 95% CI 0.44-1.30), HF (HR = 1.01, 95% CI 0.79-1.30), MACE+HF (HR = 0.90, 95% CI 0.72-1.12)”

    Humansnursing home residents1 yearn = 2,016

    Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults

    Journal of the American Geriatrics Society

More on Major adverse cardiovascular events

Blood glucose

downin humans2

2 studies
  1. DPP-4 inhibitors decrease blood glucose in humans.

    “markers regarding blood sugar were improved in both groups (all P<0.05) without intergroup differences (all P>0.05)”

    Human trialwithin-group change in patients with type 2 diabetes and post-stroke MCI; no difference from sulfonylureasix months

    Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI

    Experimental and therapeutic medicine

  2. DPP-4 inhibitors decrease blood glucose in patients with type 2 diabetes.

    “eventually decreasing the blood glucose level in patients with type 2 diabetes”

    Reviewin patients with type 2 diabetes

    Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control

    Clinical medicine insights. Endocrinology and diabetes

More on Blood glucose

TNF-alpha

downin humans1

1 study
  1. DPP-4 inhibitors decrease TNF-alpha in humans (greater reduction than sulfonylurea in patients with type 2 diabetes and post-stroke MCI).

    “tumor necrosis factor-α and interleukin-6 concentrations decreased in both groups, while the study group had greater reductions”

    Human trialgreater reduction than sulfonylurea in patients with type 2 diabetes and post-stroke MCIsix months

    Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI

    Experimental and therapeutic medicine

More on TNF-alpha

Aβ1-42/Aβ1-40 ratio

upin humans1

1 study
  1. DPP-4 inhibitors increase Aβ1-42/Aβ1-40 ratio in humans (compared with pretreatment value in patients with type 2 diabetes and post-stroke MCI).

    “the study group had higher Aβ1-42/Aβ1-40 value versus the pretreatment value (P<0.001)”

    Human trialcompared with pretreatment value in patients with type 2 diabetes and post-stroke MCIsix months

    Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI

    Experimental and therapeutic medicine

More on Aβ1-42/Aβ1-40 ratio

Cognitive ability

upin humans1

1 study
  1. DPP-4 inhibitors improve cognitive ability in humans (compared with sulfonylurea in patients with type 2 diabetes and post-stroke MCI).

    “scores regarding cognitive ability improved in the study group (both P<0.05) and were higher versus the control group (both P<0.01)”

    Human trialcompared with sulfonylurea in patients with type 2 diabetes and post-stroke MCIsix months

    Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI

    Experimental and therapeutic medicine

Triglyceride

downin humans1

1 study
  1. DPP-4 inhibitors decrease triglyceride in humans (versus placebo).

    “a significant reduction could be observed with acarbose, pioglitazone, and DPP-4 inhibitors, but not with sulfonylureas”

    Human trialversus placebo

    Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials

    Advances in therapy

More on Triglyceride

All 74

What is DPP-4 inhibitors linked with?

51

Studies link DPP-4 inhibitors with 51 measures, most often dementia (7 studies), hypoglycemia (6) and Parkinson's disease (4).

Dementia

downin humans5upin humans2HR 0.63–1.28

7 studies
  1. DPP-4 inhibitors are associated with dementia in humans (patients with diabetes mellitus; compared with sulfonylurea users).

    “Among patients with DM, low-to-intermediate cumulative exposure was associated with an increased risk of dementia”

    Humanspatients with diabetes mellitus; compared with sulfonylurea userslow-to-intermediate cumulative exposure

    Relationship between Dipeptidyl Peptidase-4 Inhibitors Use and Risk of Dementia: A Population-Based Cohort Study

    Frontiers in endocrinology

  2. DPP-4 inhibitors are linked with a higher risk of dementia in humans (HR 1.28, 95% CI 1.08-1.51).

    “DPP-4 inhibitor use was associated with higher dementia risk than SGLT2 inhibitor use (HR 1.28, 95 % CI 1.08-1.51; p = 0.005).”

    Humansin patients with type 2 diabetes after traumatic brain injury, compared with SGLT2 inhibitor usersfollow-up up to 5 yearsn = 5,357

    Comparative dementia risk associated with SGLT2 inhibitors versus DPP-4 inhibitors in patients with type 2 diabetes following traumatic brain injury: A propensity score-matched Cohort study

    Diabetes research and clinical practice

  3. DPP-4 inhibitors are linked with a lower risk of dementia in humans (matched case-control analyses).

    “In matched analyses, the use of SGLT-2 inhibitors and DPP-4 inhibitors was associated with a lower probability of dementia.”

    Humansmatched case-control analyses

    Impact of ethnicity and antihyperglycemic medications on dementia incidence in older adults with type 2 diabetes

    Endocrine connections

  4. DPP-4 inhibitors are linked with a lower risk of dementia in humans (compared with sulfonylureas) (HR 0.77, 95% CI 0.71-0.85).

    “DPP-4 inhibitors were associated with a reduced dementia risk compared with sulfonylureas (4.4 vs. 5.7 events per 1000 person-years; HR 0.77, 95% CI 0.71-0.85)”

    Humanscompared with sulfonylureasn = 275,144

    Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes

    Drug safety

  5. DPP-4 inhibitors are linked with a lower risk of dementia in humans (type 2 diabetes) (HR 0.67 [95% CI 0.63-0.71]).

    “DPP-4i, HR 0.67 [95% CI 0.63-0.71]”

    Humanstype 2 diabetesmedian 8.7 yearsn = 84,798

    New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study

    The journal of prevention of Alzheimer's disease

  6. DPP-4 inhibitors are linked with a lower risk of dementia in humans (type 2 diabetes) (HR 0.63, 95% CI 0.45-0.89).

    “the utilization of DPP4 inhibitors was associated with a decreased risk of all-cause dementia compared to metformin [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.45-0.89].”

    Humanstype 2 diabetes

    Dipeptidyl Peptidase 4 Inhibitors vs Metformin for New-onset Dementia: A Propensity Score-matched Cohort Study

    The Journal of clinical endocrinology and metabolism

  7. DPP-4 inhibitors are associated with dementia in humans (type 2 diabetes) (OR 0.86).

    “the odds ratios (OR) for reducing dementia showed SGLT2-i 0.69, GLP-1RA 0.70, DPP4-i 0.86”

    Reviewtype 2 diabetes

    Larger Relationship Between Diabetes and Alzheimer Disease and Related Dementias (ADRD)

    Journal of Health Care and Research

More on Dementia

Hypoglycemia

downin humans4upin humans2RR 1.08

6 studies
  1. DPP-4 inhibitors are linked with a lower risk of hypoglycemia in residents of LTCFs with diabetes receiving metformin compared with long-acting insulin (sHR 0.36 (95% CI, 0.23-0.56)).

    “Lower risk of hypoglycemia (sHR, 0.36; 95% CI, 0.23-0.56) and all-cause mortality (sHR, 0.82; 95% CI, 0.76-0.90) was observed in DPP-4 initiators compared with long-acting insulin.”

    Humansin residents of LTCFs with diabetes receiving metformin compared with long-acting insulin5-year follow-upn = 4,414

    Cardiovascular Safety of Dipeptidyl Peptidase 4 Inhibitors Compared With Insulin or Sulfonylureas Added to Metformin Among Older People With Diabetes Living in Long-Term Care Facilities

    Journal of the American Medical Directors Association

  2. DPP-4 inhibitors are linked with a lower risk of hypoglycemia in humans (nursing home residents) (HR = 0.57, 95% CI 0.34-0.94).

    “Compared with SU users, DPP4I users had a lower 1-year rate of severe hypoglycemic events (HR = 0.57, 95% CI 0.34-0.94)”

    Humansnursing home residents1 yearn = 2,016

    Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults

    Journal of the American Geriatrics Society

  3. DPP-4 inhibitors lower the risk of hypoglycemia in older adults with type 2 diabetes.

    “DPP-4 inhibitors (gliptins) for their better safety profile versus sulfonylureas, GLP-1 analogues or SGLT2 inhibitors (gliflozins) if cardiorenal protection is required.”

    Reviewin older adults with type 2 diabetes

    Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes

    Expert review of clinical pharmacology

  4. DPP-4 inhibitors lower the risk of hypoglycemia in humans (type 2 diabetes).

    “dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can be safely used in older patients and are preferred choices in many cases due to their safety, efficacy, and low risk of hypoglycemia”

    Reviewtype 2 diabetes

    Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes

    Endocrinology and metabolism clinics of North America

  5. DPP-4 inhibitors raise the risk of hypoglycemia in addition to standard care in older patients with type 2 diabetes (RR 1.08, 95% CI 1.01-1.16).

    “Adding DPP-4 inhibitors to standard care increases the risk for hypoglycaemia (RR 1.08; 95% CI 1.01-1.16)”

    Reviewin addition to standard care in older patients with type 2 diabetesn = 19,317

    Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

    Therapeutic advances in drug safety

  6. DPP-4 inhibitors raise the risk of hypoglycemia in addition to standard care (RR 1.08; 95%CI 1.01-1.16).

    “Adding DPP4s to standard care increases the risk for hypoglycaemia (RR 1.08; 95%CI 1.01-1.16)”

    Reviewin addition to standard care

    Safety of Dipeptidylpeptidase-4 Inhibitors in Older Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Research SquarePreprint

More on Hypoglycemia

Parkinson's disease

downin humans4OR 0.54–1.78

4 studies
  1. DPP-4 inhibitors lower the risk of Parkinson's disease in humans (OR 0.54 (95% CI 0.32–0.92)).

    “DPP4i were associated with a lower risk of certain psychiatric disorders, Parkinson's disease (0.54 [0.32, 0.92])”

    Human trial

    Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials

    Diabetes, obesity & metabolism

  2. DPP-4 inhibitors are associated with Parkinson's disease in humans (Reported OR 1.78 (95% CI 1.21-2.61) for IVeQTL; 1.21 (1.02-1.45) for IVpQTL).

    “Genetically proxied DPP-4 inhibition was associated with reduced PD risk”

    HumansGenetically proxied inhibition; direction follows the abstract's interpretation, although reported odds ratios exceed 1

    Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

  3. DPP-4 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with metformin users) (HR 0.60 (95% CI 0.53–0.67)).

    “DPP4 inhibitors (HR = 0.60, 95 % CI:0.53-0.67)”

    Humanscompared with metformin users

    Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study

    Parkinsonism & related disorders

  4. DPP-4 inhibitors are linked with a lower risk of Parkinson's disease in humans (adjusted HR 0.51 (95% CI 0.39-0.68)).

    “DPP4 inhibitor users exhibited a significantly lower risk of PD (adjusted hazard ratio, 0.51; 95% CI 0.39-0.68).”

    Humansin diabetic patients on metformin plus a second-line oral antidiabetic, propensity-score matched

    Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients

    Scientific reports

More on Parkinson's disease

Mortality

upin humans1downin humans1HR 0.762–1.26

2 studies
  1. DPP-4 inhibitors are linked with a higher risk of mortality in humans (HR 1.26; p < 0.001).

    “All-cause mortality was also higher with DPP-4 inhibitors (HR 1.26; p < 0.001).”

    Humansin patients with type 2 diabetes after traumatic brain injury, compared with SGLT2 inhibitor usersfollow-up up to 5 yearsn = 5,357

    Comparative dementia risk associated with SGLT2 inhibitors versus DPP-4 inhibitors in patients with type 2 diabetes following traumatic brain injury: A propensity score-matched Cohort study

    Diabetes research and clinical practice

  2. DPP-4 inhibitors are linked with a lower risk of mortality in humans (HR 0.762; 95% CI 0.611-0.949; p = 0.0153).

    “These findings suggest that the use of DPP4i in PD patients with co-existing DM is associated with lower risk of mortality.”

    Humanscohort compared by DPP4i use; group labels are inconsistent in the abstract, and the hazard ratio is reported for the PD-DPP4i+ groupn = 1,093

    Impact of dipeptidyl peptidase 4 inhibitor use on mortality in diabetic Parkinson's disease patients: A nationwide cohort study

    Parkinsonism & related disorders

Bullous pemphigoid

upin humans2HR 1.78

2 studies
  1. DPP-4 inhibitors are linked with a higher risk of bullous pemphigoid in humans (compared with GLP-1RA in patients with type 2 diabetes) (HR 1.78, 95% CI 1.24-2.46).

    “bullous pemphigoid (HR 1.78, 95% CI 1.24-2.46)”

    Humanscompared with GLP-1RA in patients with type 2 diabetes3 yearsn = 118,419

    Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes

    ACR open rheumatology

  2. DPP-4 inhibitors are associated with bullous pemphigoid in humans (prescribed before disease onset).

    “Dipeptidyl peptidase-4 inhibitors were more commonly prescribed before the onset of BP and EBA compared to PV and PF.”

    Humansprescribed before disease onset

    Clinical characteristics and outcomes of autoimmune blistering diseases in Japan

    The Journal of dermatology

More on Bullous pemphigoid

Osteoporosis

upin humans1downin humans1HR 1.36

2 studies
  1. DPP-4 inhibitors are linked with a higher risk of osteoporosis in humans (multivariate Cox regression; compared with metformin) (HR 1.36 (1.05–1.75)).

    “For Diabetes-related risk factors, dipeptidyl peptidase-4 inhibitors (DPP4-inhibitors), insulin, and thiazolidinediones were associated with a higher risk of osteoporosis; HR were 1.36 (1.05–1.75), 1.32 (1.05–1.65), and 1.39 (1.01–1.92), respectively.”

    Humansmultivariate Cox regression; compared with metforminn = 25,635

    Incidence and risk factors for osteoporosis in people with type 2 diabetes mellitus in Thailand

    BMC endocrine disorders

  2. DPP-4 inhibitors lower the risk of osteoporosis in humans (type 2 diabetes mellitus) (OR 0.90, 95% CI 0.86–0.94).

    “Additionally, the risk of osteoporosis was significantly reduced (OR 0.90, 95 % confidence interval 0.86-0.94)”

    Reviewtype 2 diabetes mellitus

    Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry

More on Osteoporosis

Cognitive function

no changein humans1upin humans1

2 studies
  1. DPP-4 inhibitors are associated with cognitive function in humans (type 2 diabetes).

    “No differences were observed in global cognition, attention, executive function, and semantic categorization.”

    Humanstype 2 diabetes

    Cognitive function following dipeptidyl peptidase 4 inhibitors use in older adults with type 2 diabetes: A nationwide cohort study

    AAIC 2025 abstract

  2. DPP-4 inhibitors are associated with cognitive function in humans (Slower MMSE decline: β = 0.772, SE = 0.272, p = 0.005; memory recall: β = 0.291, SE = 0.116, p = 0.012).

    “The ADCI-DPP-4i+ group showed a slower longitudinal decrease in MMSE score (β = 0.772, SE = 0.272, p = 0.005)”

    HumansPatients with diabetes and Alzheimer disease-related cognitive impairment; comparison with diabetic patients not using DPP-4 inhibitors

    Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment

    Neurology

Bone fracture

mixedin humans1downin humans1

2 studies
  1. DPP-4 inhibitors are linked with a lower risk of bone fracture in humans (ROR = 0.80; 95% CI = 0.73 - 0.88).

    “Significant inverse associations between DPP-4 inhibitor use and fracture were found for DPP-4 inhibitors as a whole (ROR = 0.80; 95% CI = 0.73 - 0.88”

    Humans

    Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER

    International journal of clinical pharmacology and therapeutics

  2. DPP-4 inhibitors are associated with bone fracture in humans (some RCTs reported bone-protective effects for certain members of the class).

    “Dipeptidyl peptidase-4 inhibitors (DPP-4is) and Glucagon-like peptide-1 receptor agonists (GLP-1Ras) were reported to have controversial effects on bone fracture”

    Reviewsome RCTs reported bone-protective effects for certain members of the class

    Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials' meta-analysis studies

    Diabetology & metabolic syndrome

More on Bone fracture

Diabetic kidney disease

downin humans1HR 0.77

1 study
  1. DPP-4 inhibitors are linked with a lower risk of diabetic kidney disease in humans (Adjusted HR 0.77, 95% CI 0.73–0.80).

    “Patients who received DPP-4is at Q3) were at a significantly lower DN risk compared with those who received a sulfonylurea”

    HumansPatients with new-onset diabetes mellitus; compared with sulfonylurea use; exposure category is malformed in the abstractQ3)5 years

    The Effect of Long-Term Use of Dipeptidyl Peptidase-4 Inhibitors on Diabetic Nephropathy Risk: A Real-World Evidence Study

    Frontiers in pharmacology

More on Diabetic kidney disease

Dementia progression

downin humans1OR 0.52

1 study
  1. DPP-4 inhibitors are associated with dementia progression in humans (Patients with dementia and type 2 diabetes; compared with non-users) (Adjusted OR 0.52, 95% CI 0.33–0.82).

    “Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) was associated with a significantly lower risk of dementia progression compared with non-users”

    HumansPatients with dementia and type 2 diabetes; compared with non-usersn = 1,007

    Dipeptidyl peptidase-4 inhibitors and slower dementia progression in patients with diabetes: A multicenter longitudinal cohort study

    Journal of Alzheimer's disease reports

Dizziness

downin humans1OR 0.76

1 study
  1. DPP-4 inhibitors lower the risk of dizziness in humans (compared with glp-1 receptor agonists) (OR 0.76 (95% CI 0.67 to 0.87)).

    “DPP-4Is had a lower risk of dizziness than GLP-1 RAs (OR: 0.76, 95% CI: 0.67 to 0.87; high quality)”

    Human trialcompared with glp-1 receptor agonists

    Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

    Aging and disease

Headache

upin humans1OR 1.22

1 study
  1. DPP-4 inhibitors raise the risk of headache in humans (compared with insulin) (OR 1.22 (95% CI 1.02 to 1.46) vs insulin).

    “DPP-4Is increased the risk of headache (OR: 1.22, 95% confidence interval [CI]: 1.02 to 1.46; moderate quality)”

    Human trialcompared with insulin

    Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

    Aging and disease

All 51

Funding

3 grants since 2017

Health and Medical Research FundHK$1.5MNovo Nordisk Foundation

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 13Jan 2026: 29Feb 2026: 29Mar 2026: 34Apr 2026: 8May 2026: 6Jun 2026: 16Jul 2026: 17Aug 2026: 23Sep 2026: 29Oct 2026: 43Nov 2026: 39286 papers in 12 months
Diabetes Research and Clinical Practice

Diabetes drug class not linked to higher kidney injury risk

After statistical adjustment, kidney injury rates were 10.5 versus 15.6 per 100,000 days of patient follow-up for two diabetes drug classes over 90 days.After statistical adjustment, kidney injury rates were 10.5 versus 15.6 per 100,000 days of patient follow-up for two diabetes drug classes over 90 days.

Cohort · 43,502 peopleType 2 diabetes

See all 514 papers on DPP-4 inhibitors